[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588215":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":25,"collaborators":11,"id":27,"slug":11,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":11,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":11,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":11,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":11},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AG+Nimotuzumab","EXPERIMENTAL",null,[13,14],"Drug: AG regimen","Drug: Nimotuzumab",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","AG regimen","Patients will receive 4 cycles of AG (gemcitabine 1000 mg\u002Fm\\^2 and nab-paclitaxel 125 mg\u002Fm\\^2 on days 1 and 8 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant AG (gemcitabine 1000 mg\u002Fm\\^2 and nab-paclitaxel 125 mg\u002Fm\\^2 on days 1 and 8 of a 21-day cycle).",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"Nimotuzumab","Patients will receive 4 cycles of Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).",[9],{"type":26,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100588215",false,"NCT06938503","AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","A Prospective, Single-Arm Study of Nab-paclitaxel\u002FGemcitabine Combined With Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* 1\\. Age 18-75 years old, gender unlimited;\n* 2\\. Histologically or cytologically confirmed pancreatic cancer;\n* 3\\. Confirmed as locally advanced pancreatic cancer by CT\u002FMRI imaging, with no evidence of distant metastasis;\n* 4\\. No prior chemotherapy or other tumor systemic therapy;\n* 5\\. Measurable disease according to RECIST criteria v1.1;\n* 6\\. Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g\u002FdL; absolute neutrophil count (ANC)≥1.5×10\\^9\u002FL; platelets≥100×10\\^9\u002FL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \\> 60 mL\u002Fmin;\n* 7\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;\n* 8\\. Life expectancy is expected to be ≥3 months;\n* 9\\. Fertile subjects are willing to take contraceptive measures during the study period.\n* 10\\. Good compliance and signed informed consent voluntarily.\n\nExclusion Criteria:\n\n* 1\\. Refuse chemotherapy or surgery;\n* 2\\. Other part (e.g. peritoneum, lung, bone, brain) metastasis;\n* 3\\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* 4\\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\\>160mmHg or DBP\\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;\n* 5\\. Undergone major surgery within 30 days;\n* 6\\. Participated in other drug related clinical trials within 4 weeks;\n* 7\\. Known allergy to prescription or any component of the prescription used in this study;\n* 8\\. With HIV, or active hepatitis (hepatitis B, hepatitis C);\n* 9\\. Failure to recover from treatment-related toxicity to ≤ grade 1 (adverse events such as alopecia judged by the researcher not to affect the treatment with the research drug are excluded);\n* 10.Other reasons that are not suitable to participate in this study according to the researcher's judgment.","ALL","18 Years","75 Years",{"count":37,"type":38},48,"ESTIMATED","INTERVENTIONAL",[41],"PHASE2","This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of nab-paclitaxel\u002Fgemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. The main endpoint is overall survival (OS).",[44],"Pancreatic Cancer, Adult","NOT_YET_RECRUITING","2025-04-14",{"date":48,"type":49},"2025-04-22","ACTUAL",{"date":51,"type":38},"2025-04-21",{"date":53,"type":38},"2028-04-28",{"name":5,"class":6}]